At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Trading 08-27 10:47:08 EDT
440.48
+0.14
+0.03%
High440.48Low431.01Vol449.00K
Open433.08D1 Closing440.34Amplitude2.15%
Mkt Cap237.19BTradable Cap236.54BTotal Shares538.48M
T/O195.78MT/O Rate0.08%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million
Reuters  ·  46 minutes ago
HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million
Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements
TIPRANKS  ·  19:15
Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements
Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints
TIPRANKS  ·  17:15
Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints
AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients
MT Newswires Live  ·  16:24
AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients
AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial
Reuters  ·  14:40
AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial
Amgen - Tezspire Safety Profile Consistent with Approved Indications
THOMSON REUTERS  ·  14:00
Amgen - Tezspire Safety Profile Consistent with Approved Indications
Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints
THOMSON REUTERS  ·  14:00
Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints
Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors
Dow Jones  ·  08-26 16:32
Sino Biopharmaceutical Stock Climbs 2.1% in Hong Kong, Outperforms Competitors
Political and General News Events from August 25
Reuters  ·  08-25 21:25
Political and General News Events from August 25
Amgen Inc. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains
Dow Jones  ·  08-25 04:34
Amgen Inc. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains
Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential
TIPRANKS  ·  08-25 00:31
Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential
Political and General News Events from August 24
Reuters  ·  08-24
Political and General News Events from August 24
Daiichi Sankyo Names Ken Keller Chief Commercialization Officer, Effective April 2027
Reuters  ·  08-24
Daiichi Sankyo Names Ken Keller Chief Commercialization Officer, Effective April 2027
Funds: What a Top Biotech Fund is Buying Now
Dow Jones  ·  08-22
Funds: What a Top Biotech Fund is Buying Now
Amgen Advances Tarlatamab Shot vs. Infusion in Phase 3 Lung Cancer Study
TIPRANKS  ·  08-22
Amgen Advances Tarlatamab Shot vs. Infusion in Phase 3 Lung Cancer Study
Amgen is Maintained at Overweight by Piper Sandler
Dow Jones  ·  08-21
Amgen is Maintained at Overweight by Piper Sandler
Amgen price target raised to $457 from $427 at Piper Sandler
TIPRANKS  ·  08-20
Amgen price target raised to $457 from $427 at Piper Sandler
Sino Biopharmaceutical Stock Climbs 13% in Hong Kong, Outperforms Competitors
Dow Jones  ·  08-20
Sino Biopharmaceutical Stock Climbs 13% in Hong Kong, Outperforms Competitors
U.S. Research Roundup-Amgen, Analog Devices, Moderna
Reuters  ·  08-20
U.S. Research Roundup-Amgen, Analog Devices, Moderna
Amgen Inc Stock (AMGN) Moved Up by 3.19% on Aug 19: What Investors Need To Know
TradingKey  ·  08-20
Amgen Inc Stock (AMGN) Moved Up by 3.19% on Aug 19: What Investors Need To Know

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--